Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of fragile X syndrome, 28/07/2015 Positive

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of fragile X syndrome, 28/07/2015 Positive

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1529https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1529
Retrieved on: 
Tuesday, April 9, 2024
Information
Tags: 
Eurostat, Fragile X syndrome, Civil service commission, Diagnosis, X chromosome, Brain, FMRP, Woman, Learning disability, Disease, Nervous system, Patient, Committee, Knowledge, History, Regulation, Traffic barrier, Anxiety, EMA, IRIS, Mouth, European, COMP, European Commission, Consultant, Safety, Marketing, DSM-IV codes, Turner syndrome, Medicine, Pharmaceutical industry
Geotags: 
EUROPEAN UNION, RARE, EC, ICELAND, EU, IRELAND, NORWAY, UNITED KINGDOM, UNITED STATES, LIECHTENSTEIN
Summary
Key Points: 


Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of fragile X syndrome, 28/07/2015 Positive

Copyright: 
2024 European Medicines Agency. All Rights Reserved.